Professional Documents
Culture Documents
Clinical Course and Management of Acute and Chronic Viral Hepatitis During Pregnancy
Clinical Course and Management of Acute and Chronic Viral Hepatitis During Pregnancy
12335
SUMMARY. Pregnancy is a para-physiologic condition, ease, and cirrhosis of different aetiologies may cause liver
which usually evolves without any complications in the damage, independently from pregnancy. In this review we
majority of women, even if in some circumstances moder- will also comment the clinical implications of pregnancies
ate or severe clinical problems can also occur. Among occurring in women who received a orthotopic liver trans-
complications occurring during the second and the third plantation (OLT) Therefore, the management of immuno-
trimester very important are those considered as concur- suppressive therapy before and after the delivery in women
rent to pregnancy such as hyperemesis gravidarum, intra- who received liver transplant is becoming a relevant clini-
hepatic cholestasis of pregnancy, HELLP syndrome and cal issue. Finally, we will focus on acute and chronic viral
acute fatty liver of pregnancy. The liver diseases concur- hepatitis occurring during pregnancy, on management of
rent to pregnancy typically occur at specific times during advanced liver disease and we will review the literature on
the gestation and they may lead to significant maternal the challenging issue regarding pregnancy and OLT.
and foetal morbidity and mortality. Commonly, delivery of
the foetus, even preterm, usually terminates the progres- Keywords: anti-viral therapy, liver disease, liver transplant,
sion of these disorders. All chronic liver diseases, such as pregnancy.
chronic viral hepatitis, autoimmune hepatitis, Wilson’s dis-
Table 1 Liver diseases concurrent or related to pregnancy, to diagnose the CMV infection. Prevention is difficult
according to trimester of gestation and liver involvement because the virus is ubiquitous and the contact is frequent.
Although controversial, some practices might minimize the
Pre-existing or Viral Hepatitis risk for congenital infection [5]. The saliva and urine of
concurrent liver
El acceso y uso a este artículo se limita exclusivamente al alumno del "Máster de Hepatología" y para los fines no lucrativos docentes y científicos del propio curso, que incluyen su análisis o comentario. Prohibida la reproducción, en cualquier formato, para otros fines o personas.
Table 2 Clinical features of acute hepatitis due to hepatotropic and nonhepatotropic viruses in pregnancy
hepatic failure, this therapeutic approach is mandatory that malnutrition and poor social conditions are the
[9,11]. main co-factors promoting this evolution [18,19]. The
reason to explain the greater susceptibility to HEV infec-
tion in pregnant women is still not known. The hypoth-
Hepatotropic viruses
esis of the reduced immunological activity and hormonal
Hepatitis A virus factors could be considered [20]. Acute HEV infection
Hepatitis A virus (HAV) can cause clinical complications if carries high mortality rates (15–25%) in pregnant
it occurs during the second/third trimester of pregnancy. women, especially in the third trimester, in association
Most of the cases are anicteric and usually mild; fulminant with acute liver failure, eclampsia and haemorrhages
hepatitis is rare [1]. It has been generally accepted that [21]. This is very common in developing countries, due
pregnancy itself does not show a negative impact on the to the emergence of genotype 3 [22]; the level of vire-
course of hepatitis A infection. However, acute HAV hepa- mia seems to be likely associated with the severity of
titis during pregnancy may be associated with a higher the disease during pregnancy [23]. The effect of acute
risk of maternal complications and therefore early delivery HEV infection on clinical course of pregnancy in Western
is indicated only in cases with severe liver dysfunction at countries is still not known [22]. Vertical transmission
the third trimester of gestation [13]. In Western countries, occurs in 50% of cases and the infection is always
HAV is not frequent. However, in developing countries, symptomatic with high rates of morbidity (hepatitis, pre-
there is a high incidence of fulminant hepatitis, probably maturity, hypothermia and hypoglycaemia) and mortality
favoured by a concomitant condition of malnutrition. In in the newborns [21].
serious cases, hospitalization is required especially when No data are available on antiviral drugs for HEV. Treat-
nausea and vomiting are severe in the last quarter and ment is only supportive. There are some reports concern-
induction of premature labour may be occur. However, ing ribavirin-based treatment, but the teratogenic effect
commonly HAV hepatitis does not represent an indication excludes any potential use in pregnant women. In case of
for Caesarean section, or early termination of pregnancy life-threatening condition of the mother, termination of
[14]. Although intrauterine transmission is rare, it has pregnancy is the rule [20–22]. Researches to develop an
been described in the presence of high levels of viral load anti-HEV vaccine are underway [2,21].
at delivery [15]. When HAV infection is diagnosed in the
third trimester, the foetus must be protected against the Hepatitis B virus
virus by administration of immune globulin within 48 h All pregnant women are routinely tested for HBsAg at first
before the birth. Breastfeeding is not contraindicated [16]. visit during gestation to screen hepatitis B virus (HBV)
infection. Acute HBV hepatitis is characterized by the
Hepatitis E virus absence of clinical complications during the course of preg-
Hepatitis E virus (HEV) hepatitis is rare in Western countries, nancy, but it carries high risk of mother-to-foetus viral
but it is endemic in several areas of Africa, Asia and Central transmission. This is particularly frequent if the mother is
America, where, if acquired during pregnancy, may show a HBeAg positive and has been infected during the third
fulminant course with a mortality rate in one of six pregnan- trimester of gestation (50–80%), but the risk of transmis-
cies [17]. Although in Western countries this is not a sion is lower when mother is anti-HBe positive (25%), or if
frequent occurrence, the HEV incidence is increased in she is asymptomatic carrier (5%) [1]. The risk of transmis-
Europe as well, especially for genotype 3 [1]. A recent sion is very low in case of maternal infection during the
French study has reported that 90% of acute hepatitis E first or second trimester of pregnancy, but increases up to
acquired in the indigenous route, so that it looks like that 50–70% if hepatitis occurs in the third trimester of preg-
current HEV epidemiology is going to change [17]. nancy or soon after birth. The main risk factor for trans-
The severe clinical course of HEV infection in preg- mission is the high viral load [24]. Consequently, antiviral
nancy differs among different Countries. It is conceivable therapy during the third trimester has the goal to reduce
viremia and so lowering the risk of perinatal transmission tion of HBIG, approximately 70–90% of infants born to
[24–26]. HBeAg-positive mothers may became chronically infected
Both telbivudine and tenofovir can be taken to prevent by HBV [26]. HBV infection does not significantly modify
intrauterine and perinatal HBV transmission during the the clinical course of pregnancy either fertility or concep-
El acceso y uso a este artículo se limita exclusivamente al alumno del "Máster de Hepatología" y para los fines no lucrativos docentes y científicos del propio curso, que incluyen su análisis o comentario. Prohibida la reproducción, en cualquier formato, para otros fines o personas.
last trimester of pregnancy in HBsAg-positive mother with tion unless the woman has liver cirrhosis or liver failure
high levels of viremia (serum HBV-DNA ≥ 106 copies/mL) [28–30]. Moreover, chronic HBV infection does not
but without significant ALT increase. The drug can be dis- increase maternal or foetal morbidity and mortality,
continued soon after the delivery if breastfeeding is planned although a recent study has shown an increased risk of
or within 3 months. diabetes mellitus, ante-partum haemorrhages and life-
Infected newborns may become chronic HBsAg carriers threatening preterm labour [30]. On the other hand, in
in 80–90% of cases together with subclinical hepatic dys- the presence of cirrhosis, the risk to develop significant
function, although they rarely will develop neonatal hepati- perinatal complications and poor pregnancy outcome is
tis. Perinatal transmission can be prevented with the use of higher [31]. Moreover, cirrhotic pregnant women have
anti-HBV vaccine and in association with hepatitis B immu- usually higher spontaneous rates of maternal complica-
noglobulin (HBIG) at birth with a percentage of success of tions such as placental abruption, gestational hypertension
about 95%. Patients at high risk of infection can be immu- and peripartum haemorrhages [1]. By the contrary, preg-
nized before or during pregnancy by HBV vaccination nancy does not influence the course of chronic HBV infec-
without any risk for the foetus [2,24]. As regard HBV/HDV tion and usually it is not considered as a possible
co-infection in pregnancy, there are very few data in worsening factor [24].
literature. Nowadays, the risk of perinatal transmission, which rep-
resents in many areas of the world the primary source of
Hepatitis C virus persistence of HBV chronic infection, has focused the atten-
The frequency of acute hepatitis C virus (HCV) infection tion to the management of HBV infection during preg-
during pregnancy is approximately calculated 0.4–6.0% nancy. The risk is very high in HBeAg-positive patients
[1]. These percentages increase in groups at high risk of with high viral load, but conflicting data exist about the
infection (like anti-HIV positive, intravenous drug users). potential role of different HBV genotypes in influencing
HCV infection can be acquired during pregnancy, but it transmission [24,32].
does not affect the course of the pregnancy. The risk of Among maternal risk factors affecting vertical or perina-
vertical transmission is very low (3–10%) and it is deter- tal transmission, we also mention placental diseases or
mined by the same risk factors of chronic hepatitis but no complications appearing during labour and breastfeeding,
therapy is available so far to avoid the contagion [27]. which is another major source of infection [24].
Routine screening is not recommended for HCV infection, Together with the immunoprophylaxis, the choice of
but it should be useful at least in ‘at risk’ groups to start correct antiviral therapy plays a major role in chronic
immediately after delivery the therapy [1]. Risk of vertical HBV-infected women. Not all available drugs for treatment
transmission is higher during delivery, due to contamina- of chronic HBV infection can be used during pregnancy,
tion with blood fluid, but it can also occur by transplacen- and they have an important role to avoid an exacerbation
tal crossing. After the delivery, maternal breastfeeding is of disease that can occur in case of drug discontinuation,
not absolutely contraindicated because risk of viral trans- especially soon after the delivery, with high risk of occur-
mission is very low during lactation and it is recommended rence of fulminant hepatitis causing a life-threatening con-
to pay attention to nipple abrasions [1,27] (http://www. dition both for mother and foetus [1,25].
cdc.gov/breastfeeding/disease/hepatitis.htm). Drugs used for the treatment of chronic hepatitis B
(CHB) include recombinant interferon (IFN), pegylated
interferon (PEG-IFN) and Nucleos(t)ides analogues (NAs).
CHRONIC VIRAL HEPATITIS
NAs are classified as nucleosides (lamivudine, telbivudine,
Chronic viral hepatitis does not adversely affect the course emtricitabine and entecavir) or nucleotides (adefovir and
of pregnancy, but it carries the risk of vertical transmission tenofovir). All these drugs have been approved in Europe
of the virus. Overall, chronic viral hepatitis is the most fre- for CHB treatment, while PEG-IFN and emtricitabine are
quent pre-existing liver disease and they need to be fol- not licensed for HBV treatment in most European coun-
lowed through the whole period of pregnancy and overall tries. Because of their possible teratogenicity, only drugs
after delivery. classified in category C or B can be used during gestation.
According to FDA classification, lamivudine, entecavir and
adefovir are classified as ‘C’, while telbivudine and tenofo-
HBV infection
vir are classified as drugs of category B (Table 3). Until
HBV is an important global health problem, because of now, the more appropriate drug is tenofovir because many
high risk of perinatal viral transmission. Before the adop- data are available about the safety profile in pregnancy.
Table 3 Drugs for liver diseases and their use in women during pregnancy and after delivery
FDA Effect on
Class Drug pregnancy conception Effect on foetus Breastfeeding
El acceso y uso a este artículo se limita exclusivamente al alumno del "Máster de Hepatología" y para los fines no lucrativos docentes y científicos del propio curso, que incluyen su análisis o comentario. Prohibida la reproducción, en cualquier formato, para otros fines o personas.
Furthermore, several data above safety of tenofovir are the delivery; in women with an advanced fibrosis or cir-
reported in HIV patients showing very low rate of congeni- rhosis, therapy is mandatory [25]. During pregnancy, ther-
tal abnormalities [33]. By contrast, PEG-IFN is absolutely apy must be based on a NA of category B, possibly
contraindicated because of high teratogenicity risk. In fact, tenofovir. If pregnancy is accidental and not planned, ther-
women or partners of patients treated with PEG-IFN or in apy should be adjusted and modified with a NA of cate-
childbearing age should use a good contraception system gory B [1].
until three to 6 months after stopping antiviral therapy HBV infection can be transmitted from mother-to-foetus
[34]. at delivery. This risk, as mentioned before, correlates with
Regarding to the different pharmacological features and viral load and HBeAg positivity. The prevention of HBV
teratogenicity risks of drugs for treating a young woman perinatal transmission is traditionally based on the combi-
chronically HBV infected that wish to become pregnant nation of passive and active immunization with HBIG and
should dispose her pregnancy and should be educated HBV vaccination. Such a strategy, however, may not be
about safety profile of drugs during pregnancy. According effective in a proportion of newborns from highly viremic
to the last EASL guidelines, the therapeutic approach may women (serum HBV-DNA >106–7 copies/mL), which carry
be different based on the severity of liver damage: in a risk of vertical HBV transmission more than 10% despite
women that want to become pregnant and do not have administration of HBIG and vaccination. In these cases,
an advanced fibrosis, it is advisable to delay therapy after the use of NAs before delivery may reduce viral loads and
therefore improve the effectiveness of HBIG and vaccina- to observe during pregnancy a decrease of aminotransfe-
tion [35]. rases and an increase of HCV viral load, followed by an
Therapy with lamivudine and, more recently, with tel- inversion of parameters during the postpartum period
bivudine [36] during the last trimester in HBsAg-positive [1,43]. It has also been observed an increase of cases
El acceso y uso a este artículo se limita exclusivamente al alumno del "Máster de Hepatología" y para los fines no lucrativos docentes y científicos del propio curso, que incluyen su análisis o comentario. Prohibida la reproducción, en cualquier formato, para otros fines o personas.
women with high viral load has been shown to be safe with cholestasis of pregnancy in anti-HCV-positive women
and to reduce the risk of intrauterine and perinatal trans- [44]. The benign course of disease observed during preg-
mission of HBV if given in addition to passive and active nancy is attributed to the production of endogenous IFN
vaccination by HBIG and HBV vaccination after delivery. by foetus and placenta [45]. The ALT levels decrease in
No controlled clinical trial of tenofovir to prevent perinatal association with viral load increase observed during the
transmission has been carried out until now. third trimester of pregnancy in women chronically
There is not contraindication of breastfeeding for HBsAg- infected by HCV could conceivably be explained by a
positive mother, even if HBV-DNA has been found in pregnancy-associated decline in immune-mediated hepato-
maternal milk [37]. No studies are available about safety cellular destruction and change of immunological state
of NAs use during the breastfeeding. For mothers on antiv- [40,46].
iral therapy with lamivudine or tenofovir, breastfeeding is Multiple host factors have been shown to increase the
not recommended because few data are available about risk of HCV MTCT; some of them are unchangeable, such
the safety of antiviral exposure during breastfeeding as elevated viral load, co-infection with HIV, abuse of
[33,37]; however, due to low oral bioavailability of tenofo- drugs and alcohol, other are mainly related to delivery
vir in maternal milk, the newborn should not considered management including amniocentesis and prolonged rup-
to be at risk [33,38,39]. ture of membranes [42]. Viral transmission can occur both
As regarding to HBV/HDV co-infection, clinical course of in the uterus and during delivery. Indeed, perinatal HCV
HDV infection in pregnancy is similar in pregnant and transmission is almost restricted to women with detectable
nonpregnant women, although the clinical suspicion of HCV-RNA in the peripheral blood and MTCT rarely occurs
this possible disease should arise in pregnant women with if the maternal viral load remains below 100 000 HCV-
acute or chronic hepatitis B with a reactivation or hyper- RNA IU/mL [47]. However, there is a broad overlap in the
transaminasemia, testing for anti-HDV. This is extremely levels of plasma HCV-RNA between transmitting and non-
uncommon; however, because the vaccination for hepatitis transmitting mothers [48].
B, when given to newborns infants, is almost uniformly The risk of vertical transmission is related to viral load.
effective against hepatitis D. Vertical transmission has not Hence, the achievement of viral clearance would be desir-
been shown, so early delivery is not necessary. Breastfeed- able before pregnancy because there are no drugs for HCV
ing is safe, and vertical transmission can be avoided using infection usable during gestation to reduce the risk of
HBV immunoprophylaxis [38]. transmission.
Women with HCV infection can plan a pregnancy, and
they must be educated about high teratogenicity risks of
HCV infection
therapy during pregnancy. HCV-infected women, treated
Prevalence of HCV infection in pregnant women ranges with standard therapeutic approach, must attend at least
between 1% and 2% in the United States and Europe, but 6 months before becoming pregnant. If they accidentally
it could increase up to 8% in some developing countries. become pregnant, therapy must be stopped and the mother
HCV mother-to-child transmission (MTCT) has been clearly should be informed for the risks of teratogenicity
documented, with reported rates of about 5–10% [1,40]. [1,49,50].
Pathogenesis of HCV infection in pregnancy and during HCV-infected pregnant women do not need special moni-
the neonatal period remains poorly understood. During toring, but only prenatal routine care as noninfected preg-
gestation, a modulation of immune responses differs nant women. Delivery modalities usually do not influence
between the different stages of pregnancy [41,42]. In fact, vertical transmission, and Caesarean section is not consid-
at the same time, the maternal immune system must ered a modality to prevent vertical transmission [43].
develop tolerance to paternal alloantigens to prevent Data on transmission of HCV during lactation are con-
maternal immune aggression against the foetus and main- tradictory. It has been suggested a correlation between dis-
tain active immunity against HCV to protect both mother ease activity (raised transaminases and HCV-RNA positive)
and foetus from the infection [41]. and detection of HCV-RNA in breast milk resulting a
Although HCV affects a significant number of women chance of increased disease transmission by this route
of reproductive age, few studies have examined the [42,49]. On the other hand, in several studies, transmis-
impact of chronic HCV infection on pregnancy outcomes. sion of HCV by breastfeeding has not been demonstrated,
Pregnancy does not seem to adversely affect the clinical so there are no specific contraindications of breastfeeding
course of HCV infection [43]. The majority of pregnant in HCV-infected women [1,50]. Infected children can be
anti-HCV-positive women are asymptomatic. It is possible treated with the available options but usually they can be
treated only after the third year of age because of the routine practice. If possible, a vaginal delivery is desirable
adverse effects of treatment on growth [51]. However, [1].
spontaneous resolution of infection has been observed both As regard to other sequelae related to cirrhosis (ascites,
in mother during the postpartum period and in foetus spontaneous bacterial peritonitis, portosystemic encepha-
El acceso y uso a este artículo se limita exclusivamente al alumno del "Máster de Hepatología" y para los fines no lucrativos docentes y científicos del propio curso, que incluyen su análisis o comentario. Prohibida la reproducción, en cualquier formato, para otros fines o personas.
such as azathioprine, cyclosporine and mycophenolic acid As regard to breastfeeding mothers with OLT can safely
have been shown to be teratogenic in animals. The risk of use prednisone or other glucocorticoids. The infant expo-
birth defects is almost similar for all agents; some drugs, like sure of tacrolimus with milk is very low, and therefore, its
calcineurin inhibitors can lead to prematurity risk and oth- administration may be compatible with breastfeeding. Data
El acceso y uso a este artículo se limita exclusivamente al alumno del "Máster de Hepatología" y para los fines no lucrativos docentes y científicos del propio curso, que incluyen su análisis o comentario. Prohibida la reproducción, en cualquier formato, para otros fines o personas.
ers (like cyclosporine) could have their effect on renal func- collected from the NTPR indicate no adverse outcomes in
tion increasing the risk of pre-eclampsia [58]. Tacrolimus infants who were breastfed during maternal cyclosporine
seems to give lower incidence of complications gaining a bet- use; insufficient evidence is present in the literature about
ter control of hepatic function [60]. Obviously, hepatic func- azathioprine’s teratogenicity [2]. Nevertheless, it is advised
tion must be strictly checked along the whole pregnancy to avoid breast feed in the first few months post-transplan-
and every abnormalities should be managed in the same tation where immunosuppressive therapy is at high serum
way as in nonpregnant women [2]. level.
REFERENCES
1 Hay JE. Liver disease in pregnancy. van Doornum GJ. Quantification of infection in pregnancy in Ethiopia.
Hepatology 2008; 47: 1067–1076. viral DNA and liver enzymes in Ethiop Med J 1993; 31: 173–181.
2 Hammoud GM, Almashhrawi AA, plasma improves early diagnosis 20 Pal R, Aggarwal R, Naik SR, Das V,
Ahmed KT, Rahman R, Bah JA. and management of herpes simplex Das S, Naik S. Immunological alter-
Liver diseases in pregnancy: liver virus hepatitis. J Viral Hepat 2011; ations in pregnant women with
transplantation in pregnancy. World 18: e160–e166. acute hepatitis E. J Gastroenterol
J Gastroenterol 2013; 19: 7647– 11 Allen RH, Tuomala RE. Herpes sim- Hepatol 2005; 20: 1094–1101.
7651. plex virus hepatitis causing acute 21 Aggarwal R, Jameel S. Hepatitis E.
3 Lee M, Brady W. Liver disease in liver dysfunction and thrombocyto- Hepatology 2011; 54: 2218–2226.
pregnancy. World J Gastroenterol penia in pregnancy. Obstet Gynecol 22 Sclair SN, Schiff ER. An update on
2009; 15: 897–906. 2005; 106: 1187–1189. the hepatitis E virus. Curr Gastroen-
4 Alvaro E, Jimenez LC, Palomo I et al. 12 Glaxo Wellcome Inc. Zovirax terol Rep 2013; 15: 304.
Pregnancy and orthotopic liver (acyclovir) Product Information. 23 Borkakoti J, Hazam RK, Mohammad
transplantation. Transplant Proc Boronia, Vic.: Glaxo Wellcome Inc, A, Kumar A, Kar P. Does high viral
2013; 45: 1966–1968. 1996. load of hepatitis E virus influence
5 Lazzarotto T, Guerra B, Gabrielli L, 13 Martin A, Lemon SM. Hepatitis A the severity and prognosis of acute
Lanari M, Landini MP. Update on virus: from discovery to vaccines. liver failure during pregnancy? J
the prevention, diagnosis and man- Hepatology 2006; 43(2 Suppl. 1): Med Virol 2013; 85: 620–626.
agement of cytomegalovirus infec- S164–S172. 24 Piratvisuth T. Optimal management
tion during pregnancy. Clin 14 Motte A, Blanc J, Minodier P, Col- of HBV infection during pregnancy.
Microbiol Infect 2011; 17: 1285– son P. Acute hepatitis A in a preg- Liver Int 2013; 33(Suppl. 1): 188–
1293. nant woman at delivery. Int J Infect 194.
6 Nigro G, Adler SP, La Torre R, Best Dis 2009; 13: e49–e51. 25 European Association for the Study
AM; Congenital Cytomegalovirus 15 Leikin E, Lysikiewicz A, Garry D, of the Liver. EASL clinical practice
Collaborating Group. Passive immu- Tejani N. Intrauterine transmission guidelines: management of chronic
nization during pregnancy for con- of hepatitis A virus. Obstet Gynecol hepatitis B virus infection. J Hepatol
genital cytomegalovirus infection. N 1996; 88: 690–691. 2012; 57: 167–185.
Engl J Med 2005; 353: 1350–1362. 16 Fiore AE, Shapiro CN, Sabin K et al. 26 Beasley RP, Trepo C, Stevens CE,
7 Jacquemard F, Yamamoto M, Costa Hepatitis A vaccination of infants: Szmuness W. The e antigen and
JM et al. Maternal administration of effect of maternal antibody status vertical transmission of hepatitis B
valaciclovir in symptomatic intra- on antibody persistence and surface antigen. Am J Epidemiol
uterine cytomegalovirus infection. response to a booster dose. Pediatr 1977; 105: 94–98.
BJOG 2007; 114: 1113–1121. Infect Dis J 2003; 22: 354–359. 27 Mast EE, Hwang LY, Seto DS et al.
8 Norvell JP, Blei AT, Jovanovic BD, 17 Renou C, Moreau X, Pariente A Risk factors for perinatal transmis-
Levitsky J. Herpes simplex virus hep- et al. A national survey of acute sion of hepatitis C virus (HCV) and
atitis: analysis of the published liter- hepatitis E in France. Aliment the natural history of HCV infection
ature and institutional cases. Liver Pharmacol Ther 2008; 27: 1086– acquired in infancy. J Infect Dis
Transpl 2007; 13: 1428–1434. 1093. 2005; 192: 1880–1889.
9 Brown ZA, Selke S, Zeh J et al. The 18 Navaneethan U, Mohajer MA, Shat- 28 Tan J, Surti B, Saab S. Pregnancy
acquisition of herpes simplex virus a MT. Hepatitis E and pregnancy: and cirrhosis. Liver Transpl 2008;
during pregnancy. N Engl J Med understand the pathogenesis. Liver 14: 1081–1091.
1997; 337: 509–515. Int 2008; 28: 1190–1198. 29 Pan CQ, Duan ZP, Bhamidimarri
10 Beersma MF, Verjans GM, Metselaar 19 Tsega E, Krawczynski K, Hansson KR et al. An Algorithm for risk
HJ, Osterhaus AD, Berrington WR, BG, Nordenfelt E. Hepatitis E virus assessment and intervention of
mother to child transmission of hep- genesis of hepatitis C during C-positive women? J Fam Pract
atitis B virus. Clin Gastroenterol Hep- pregnancy and childhood. Viruses 2010; 59: 289–290.
atol 2012; 10: 452–459. 2012; 4: 3531–3550. 51 Arshad M, El-Kamary SS, Jhaveri R.
30 Tse KY, Ho LF, Lao T. The impact of 41 Mor G, Cardenas I. The immune Hepatitis C virus infection during
maternal HBsAg carrier status on system in pregnancy: a unique pregnancy and the newborn period–
El acceso y uso a este artículo se limita exclusivamente al alumno del "Máster de Hepatología" y para los fines no lucrativos docentes y científicos del propio curso, que incluyen su análisis o comentario. Prohibida la reproducción, en cualquier formato, para otros fines o personas.
pregnancy outcomes: a case–control complexity. Am J Reprod Immunol are they opportunities for treatment?
study. J Hepatol 2005; 43: 771–775. 2010; 63: 425–433. J Viral Hepat 2011; 18: 229–236.
31 Degli Esposti S, Shah D. Hepatitis B 42 Floreani A. Hepatitis C and preg- 52 Garg V, van Heeswijk R, Yang Y,
in pregnancy: challenges and treat- nancy. World J Gastroenterol 2013; Kauffman R, Smith F, Adda N.
ment. Gastroenterol Clin North Am 19: 6714–6720. The pharmacokinetic interaction bet-
2011; 40(2): 355–372. 43 Pergam SA, Wang CC, Gardella CM, ween an oral contraceptive contain-
32 Borgia G, Carleo MA, Gaeta GB, Sandison TG, Phipps WT, Hawes ing ethinylestradiol and norethin-
Gentile I. Hepatitis B in pregnancy. SE. Pregnancy complications associ- drone and the HCV protease
World J Gastroenterol 2012; 18: ated with hepatitis C: data from a inhibitor telaprevir. J Clin Pharmacol
4677–4683. 2003–2005 Washington state birth 2012; 52: 1574–1583.
33 Foster C, Lyall H, Olmscheid B, Pe- cohort. Am J Obstet Gynecol 2008; 53 Russell MA, Craigo SD. Cirrhosis
arce G, Zhang S, Gibb DM. Tenofovir 199: 38.e1–38.e9. and portal hypertension in preg-
disoproxil fumarate in pregnancy 44 Paternoster DM, Fabris F, Pal u G nancy. Semin Perinatol 1998; 22:
and prevention of mother-to-child et al. Intra-hepatic cholestasis of 156–165.
transmission of HIV-1: is it time to pregnancy in hepatitis C virus infec- 54 Shaheen AA, Myers RP. The out-
move on from zidovudine? HIV Med tion. Acta Obstet Gynecol Scand comes of pregnancy in patients with
2009; 10: 397–406. 2002; 81: 99–103. cirrhosis: a population-based study.
34 Keefe EB, Dieterich DT, Han S-HB 45 Paternoster DM, Belligoli A, Ngara- Liver Int 2010; 30: 275–283.
et al. A treatment algorithm for the doumbe NK et al. Endogenous inter- 55 Cheng YS. Pregnancy in liver cir-
management of chronic hepatitis B feron-alpha level is increased in rhosis and/or portal hypertension.
virus infection in the United States: hepatitis C virus (HCV)-positive Am J Obstet Gynecol 1977; 128:
an update. Clin Gastroenterol Hepatol pregnant women. J Clin Gastroenter- 812–822.
2006; 4: 936–962. ol 2008; 42: 204–207. 56 Misra S, Sanyal AJ. Pregnancy in a
35 Nguyen G, Garcia RT, Nguyen N, 46 Gervais A, Bacq Y, Bernuau J et al. patient with portal hypertension.
Trinh H, Keeffe EB, Nguyen MH. Decrease in serum ALT and Clin Liver Dis 1999; 3: 147–162.
Clinical course of hepatitis B virus increase in serum HCV RNA during 57 Helmy A, Hayes PC. Review article:
infection during pregnancy. Aliment pregnancy in women with chronic current endoscopic therapeutic
Pharmacol Ther 2009; 29: 755–764. hepatitis C. J Hepatol 2000; 32: options in the management of vari-
36 Liu M, Cai H, Yi W. Safety of telbivu- 293–299. ceal bleeding. Aliment Pharmacol
dine treatment for chronic hepatitis 47 Roberts EA, Yeung L. Maternal- Ther 2001; 15(5): 575–594.
B for the entire pregnancy. J Viral infant transmission of hepatitis C 58 Coscia LA, Constantinescu S, Moritz
Hepat 2013; 20(Suppl. 1): 65–70. virus infection. Hepatology 2002; 36 MJ et al. Report from the National
37 Chen X, Chen J, Wen J et al. Breast- (5 Suppl. 1): S106–S113. Transplantation Pregnancy Registry
feeding is not a risk factor for 48 Indolfi G, Resti M. Perinatal trans- (NTPR): outcomes of pregnancy
mother-to-child transmission of hep- mission of hepatitis C virus infec- after transplantation. Clin Transpl
atitis B virus. PLoS One 2013; 8: tion. J Med Virol 2009; 81: 836– 2010; 65–85. PMID: 21698831.
e55303. 843. 59 Armenti VT. Pregnancy after liver
38 Bzowej NH. Hepatitis B therapy in 49 Pembrey L, Newell ML, Tovo PA, transplantation. Liver Transpl 2012;
pregnancy. Curr Hepat Rep 2010; 9: EPHN Collaborators. The manage- 18: 619–620.
197–204. ment of HCV infected pregnant 60 Paternoster DM, Floreani A, Burra
39 Valdes R, Sep ulveda MA, Candia women and their children European P. Liver transplantation and preg-
PP, Lattes AK. Acute viral hepatitis paediatric HCV network. J Hepatol nancy. Int J Gynaecol Obstet 1995;
during pregnancy. Rev Chilena Infec- 2005; 43: 515–525. 50(2): 199–200.
tol 2010; 27: 505–512. 50 Powell M, Bailey J, Maggio LA. Clin-
40 Le Campion A, Larouche A, Fau- ical inquiries. How should you
teux-Daniel S, Soudeyns H. Patho- manage children born to hepatitis